DPP4 and colorectal carcinoma: Overall, studies investigating CD26+ subsets may ultimately contribute to the development of new treatment options for CRC (Cheung et al., 2017; LaBarge and Bissell, 2008; Han et al., 2013, 2011; Qiu et al., 2015; Osawa et al., 2016; Cutler et al., 2015; Khurana et al., 2013).